ENTOURAGE HEALTH CORP (ENTG.CA)

CA2938611001 - Common Stock

0.01  0 (0%)

Fundamental Rating

1

Overall ENTG gets a fundamental rating of 1 out of 10. We evaluated ENTG against 37 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ENTG have multiple concerns. ENTG does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ENTG has reported negative net income.
ENTG had a negative operating cash flow in the past year.
ENTG had negative earnings in each of the past 5 years.
In the past 5 years ENTG always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of ENTG (-182.45%) is worse than 85.29% of its industry peers.
Industry RankSector Rank
ROA -182.45%
ROE N/A
ROIC N/A
ROA(3y)-155.61%
ROA(5y)-104.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ENTG's Gross Margin of 12.37% is on the low side compared to the rest of the industry. ENTG is outperformed by 76.47% of its industry peers.
In the last couple of years the Gross Margin of ENTG has remained more or less at the same level.
ENTG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 12.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y0.13%

More info and screens

0

2. Health

2.1 Basic Checks

ENTG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ENTG has been increased compared to 1 year ago.
ENTG has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ENTG is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -31.14, we must say that ENTG is in the distress zone and has some risk of bankruptcy.
ENTG's Altman-Z score of -31.14 is on the low side compared to the rest of the industry. ENTG is outperformed by 91.18% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -31.14
ROIC/WACCN/A
WACC0.91%

2.3 Liquidity

ENTG has a Current Ratio of 0.10. This is a bad value and indicates that ENTG is not financially healthy enough and could expect problems in meeting its short term obligations.
ENTG's Current ratio of 0.10 is on the low side compared to the rest of the industry. ENTG is outperformed by 94.12% of its industry peers.
ENTG has a Quick Ratio of 0.10. This is a bad value and indicates that ENTG is not financially healthy enough and could expect problems in meeting its short term obligations.
ENTG has a Quick ratio of 0.04. This is amonst the worse of the industry: ENTG underperforms 94.12% of its industry peers.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.04

More info and screens

3

3. Growth

3.1 Past

ENTG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.08%, which is quite impressive.
The Revenue has decreased by -0.29% in the past year.
Measured over the past years, ENTG shows a very strong growth in Revenue. The Revenue has been growing by 38.62% on average per year.
EPS 1Y (TTM)65.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.38%
Revenue 1Y (TTM)-0.29%
Revenue growth 3Y11.42%
Revenue growth 5Y38.62%
Sales Q2Q%-8.95%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENTG. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ENTG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENTOURAGE HEALTH CORP

TSX-V:ENTG (12/24/2024, 7:00:00 PM)

0.01

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-28 2024-11-28
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.54%
Ins Owner ChangeN/A
Market Cap3.07M
Analysts45.71
Price Target0.05 (400%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.08
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.14
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.13
BVpS-0.53
TBVpS-0.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -182.45%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 12.37%
FCFM N/A
ROA(3y)-155.61%
ROA(5y)-104.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y0.13%
F-Score4
Asset Turnover1.7
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 267.27%
Cap/Sales 3.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.1
Quick Ratio 0.04
Altman-Z -31.14
F-Score4
WACC0.91%
ROIC/WACCN/A
Cap/Depr(3y)116.21%
Cap/Depr(5y)4125.57%
Cap/Sales(3y)2.76%
Cap/Sales(5y)56.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.38%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.29%
Revenue growth 3Y11.42%
Revenue growth 5Y38.62%
Sales Q2Q%-8.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y52.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y76.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.19%
OCF growth 3YN/A
OCF growth 5YN/A